Get started
Author

А. Н. Багликов

Observed names: A Baglikov, A N Baglikov, A. Baglikov, A. N. Baglikov, Andrey Baglikov, А Н Багликов
ORCID: 0009-0009-4667-4071
Observed ORCID: 0009-0009-4667-4071
OpenAlex ID: A5009616998
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
2019 · Deepak L Bhatt, Philippe Gabriel Steg, et al. · The Lancet · 211
Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction
2021 · Burkert Pieske, Rolf Wachter, et al. · JAMA · 172
PDF
NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction
2020 · Domingo Pascual-Figal, Rolf Wachter, et al. · JACC Heart Failure · 42
PDF
Presentation, care, and outcomes of patients with NSTEMI according to World Bank country income classification: the ACVC-EAPCI EORP NSTEMI Registry of the European Society of Cardiology
2023 · Ramesh Nadarajah, Peter Ludman, et al. · European Heart Journal - Quality of Care and Clinical Outcomes · 24
PDF
Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II)
2017 · Sergey Boytsov, Natalia Logunova, et al. · Cardiovascular Diabetology · 21
PDF
Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry
2022 · Ramesh Nadarajah, Peter Ludman, et al. · European Heart Journal - Quality of Care and Clinical Outcomes · 20
PDF
COMPARISON OF THE ORIGINAL (PLAVIx) AND GENERIC (CLAPITAx) CLOPIDOGREL ON PLATELET AGGREGATION: ObSERVATIONAL STUDY
2018 · A. S. Skotnikov, Zh. M. Sizova, et al. · Russian Journal of Cardiology · 5
PDF
Possibilities of Optimizing Drug Therapy for Myocardial Infarction: a Consensus on the Use of Type 2 Sodium-Glucose Co-Transporter Inhibitors. Conciliation Document of the Expert Group
2025 · G. P. Arutyunov, S. K. Kononov, et al. · Kardiologiia · 2
PDF
Perfect storm: a clinical case of multisite (brain, coronary, renal and spleen) embolism in patient with atrial fibrillation
2023 · N. I. Novitsky, A. N. Baglikov, et al. · Russian Journal of Cardiology · 1
PDF
Особенности Клинической Фармакологии Ацетилсалициловой Кислоты Как Антитромботического Препарата
2019 · В В Рафальский, A.V. Krikova, et al. · DOAJ (DOAJ: Directory of Open Access Journals) · 1
Risk stratification of major adverse cardiovascular events in heart failure patients undergoing coronary artery bypass grafting: an observational multicenter prospective study (PROFILE-HF)
2026 · A. A. Garganeeva, E. A. Kuzheleva, et al. · Сибирский журнал клинической и экспериментальной медицины
PDF
Assessment of regional variation in the management of heart failure with a preserved ejection fraction between the Russian Federation and the European Union: the results of the international survey
2026 · Anastasia Shchendrygina, Irina Komarova, et al. · Global Cardiology Science and Practice
Assessment of regional variation in the management of heart failure with a preserved ejection fraction between the Russian Federation and the European Union: the results of the international survey
2025 · Elena Kuzheleva, Clara Saldarriaga, et al. · BMJ Open
Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge in Russian practice
2013 · A. Baglikov, V. Rafalskiy · European Heart Journal
Compliance as the major effectiveness determinant in preventive acetylsalicylic acid therapy
2011 · V. V. Rafalskiy, A. N. Baglikov · CARDIOVASCULAR THERAPY AND PREVENTION
PDF
Комплаентность - Определяющий Фактор Эффективности Профилактического Применения Ацетилсалициловой Кислоты
2011 · В В Рафальский, А Н Багликов · CARDIOVASCULAR THERAPY AND PREVENTION
Сравнительная Оценка Кишечнорастворимых Таблеток Ацетилсалициловой Кислоты Разных Производителей По Тесту “растворение”
2010 · В В Рафальский, Лосенкова С.О, et al. · CyberLeninK (CyberLeninka)
Approaches to the rational choice of type 5 phosphodiesterase inhibitors in patients presenting with cardiovascular and endocrine diseases
2010 · V V Rafal'skiĭ, A N Baglikov · Problems of Endocrinology
Comparison of Enteric-coated Aspirin Tablets by Different Producers: Dissolution Test Results
2010 · V. V. Rafalsky, S. O. Losenkova, et al. · Russian Cardiology Journal (Russian Cardiology Society)
PDF
Подходы к рациональному выбору ингибиторов фосфодиэстеразы 5-го типа у пациентов с сердечно-сосудистыми и эндокринными заболеваниями
2010 · В В Рафальский, А. Н. Багликов · CyberLeninK (CyberLeninka)
Works count: 20
Citation count: 499
H-index: 6
I10-index: 6
Year
Topic
Type